COST EFFECTIVENESS MODEL OF ATEZOLIZUMAB PLUS BEVACIZUMAB IN UNTREATED LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA (HCC) IN FRENCH SETTING

This cost effectiveness analysis was performed following atezolizumab in combination with bevacizumab (ATZ+BVA) established as a new standard of care in adult with unresectable hepatocarcinoma, non-eligible to chemo-embolization in France, with the latest cut off (Aug 2020) of IMbrave150 study.